Acurx Pharmaceuticals Inc... (ACXP)
NASDAQ: ACXP
· Real-Time Price · USD
7.03
-0.10 (-1.40%)
At close: Oct 16, 2025, 3:59 PM
7.11
1.14%
After-hours: Oct 16, 2025, 07:58 PM EDT
-1.40% (1D)
| Bid | 6.75 |
| Market Cap | 11.14M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10M |
| EPS (ttm) | -10.57 |
| PE Ratio (ttm) | -0.67 |
| Forward PE | -1.74 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 7.29 |
| Volume | 198,574 |
| Avg. Volume (20D) | 568,478 |
| Open | 7.08 |
| Previous Close | 7.13 |
| Day's Range | 6.76 - 7.26 |
| 52-Week Range | 3.80 - 41.00 |
| Beta | -1.29 |
| Ex-Dividend Date | n/a |
About ACXP
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ACXP
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ACXP stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 months ago
-12.25%
Acurx Pharmaceuticals shares are trading lower aft...
Unlock content with
Pro Subscription
4 months ago
+167.26%
Acurx Pharmaceuticals shares are trading higher after the company announced publication of its Phase 2 ibezapolstat study results in The Lancet.
2 months ago · seekingalpha.com
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2025 Earnings Call TranscriptAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q2 2025 Earnings Conference Call August 12, 2025 8:00 AM ET Company Participants David P. Luci - Co-Founder, President, CEO, Corporate Secretary & Director R...